[go: up one dir, main page]

MX2023005379A - Novel linkers of multispecific antigen binding domains. - Google Patents

Novel linkers of multispecific antigen binding domains.

Info

Publication number
MX2023005379A
MX2023005379A MX2023005379A MX2023005379A MX2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A MX 2023005379 A MX2023005379 A MX 2023005379A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding domains
multispecific antigen
multispecific
novel linkers
Prior art date
Application number
MX2023005379A
Other languages
Spanish (es)
Inventor
Timothy Riley
Zhulun Wang
Darren L Bates
Bram Estes
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023005379A publication Critical patent/MX2023005379A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The ability to generate a single antibody-based construct that can recognize multiple targets simultaneously, is paramount to advance many therapeutics candidates to clinic. Often, this implies extensive protein design with vary degrees of success. In the case of multispecific antibodies, the driving of the HC/LC pairing in the Fab region represents one of the most difficult challenges yet in the field of multispecific engineering. Described here is the discovery of a new single chain Fab module that utilizes a novel linker between VL-CL and VH-CH1 domains which will further enable the production of multispecifics.
MX2023005379A 2020-11-10 2021-11-09 Novel linkers of multispecific antigen binding domains. MX2023005379A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063112119P 2020-11-10 2020-11-10
PCT/US2021/058669 WO2022103773A1 (en) 2020-11-10 2021-11-09 Novel linkers of multispecific antigen binding domains

Publications (1)

Publication Number Publication Date
MX2023005379A true MX2023005379A (en) 2023-05-23

Family

ID=78821254

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005379A MX2023005379A (en) 2020-11-10 2021-11-09 Novel linkers of multispecific antigen binding domains.

Country Status (8)

Country Link
US (1) US20240002545A1 (en)
EP (1) EP4244246A1 (en)
JP (1) JP2023548595A (en)
AU (1) AU2021379598A1 (en)
CA (1) CA3200603A1 (en)
MX (1) MX2023005379A (en)
TW (1) TW202233663A (en)
WO (1) WO2022103773A1 (en)

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DK0463151T3 (en) 1990-01-12 1996-07-01 Cell Genesys Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
JP2938569B2 (en) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド Method for producing xenogeneic immunoglobulin and transgenic mouse
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
DE69224906T2 (en) 1991-07-08 1998-10-29 Univ Massachusetts THERMOTROPES LIQUID CRYSTALLINE SEGMENT BLOCK COPOLYMER
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
DE69637481T2 (en) 1995-04-27 2009-04-09 Amgen Fremont Inc. Human antibodies to IL-8 derived from immunized Xenomae
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
MX2007002856A (en) 2004-09-02 2007-09-25 Genentech Inc Heteromultimeric molecules.
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
IN2009DN05758A (en) 2007-03-12 2015-07-24 Esbatech Ag
MX2009010282A (en) 2007-03-29 2009-10-12 Genmab As Bispecific antibodies and methods for production thereof.
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
KR101431318B1 (en) * 2009-04-02 2014-08-20 로슈 글리카트 아게 Multispecific antibodies comprising full length antibodies and single chain fab fragments
ES2989108T3 (en) 2010-04-20 2024-11-25 Genmab As Proteins containing heterodimeric antibody FC and methods for producing the same
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
DK2794905T3 (en) * 2011-12-20 2020-07-06 Medimmune Llc MODIFIED POLYPEPTIDES FOR BISPECIFIC ANTIBODY BASIC STRUCTURES
UY35148A (en) * 2012-11-21 2014-05-30 Amgen Inc HETERODIMERIC IMMUNOGLOBULINS
KR20200140878A (en) * 2018-04-09 2020-12-16 암젠 인크 Growth differentiation factor 15 fusion protein
WO2020085827A1 (en) * 2018-10-24 2020-04-30 주식회사 툴젠 Modified immunocytes
US20220152154A1 (en) * 2019-03-08 2022-05-19 Amgen Inc. Growth differentiation factor 15 combination therapy

Also Published As

Publication number Publication date
TW202233663A (en) 2022-09-01
WO2022103773A1 (en) 2022-05-19
JP2023548595A (en) 2023-11-17
AU2021379598A1 (en) 2023-06-08
EP4244246A1 (en) 2023-09-20
US20240002545A1 (en) 2024-01-04
CA3200603A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
MX2023002125A (en) Antigen binding proteins with non-canonical disulfide in fab region.
RU2011143905A (en) POLYSPECIFIC ANTIBODIES INCLUDING FULL LENGTH ANTIBODIES AND SINGLE-CHAIN Fragments Fab
EA202092839A1 (en) PSMA LINKING AGENTS AND THEIR APPLICATIONS
CY1124691T1 (en) BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3
WO2012023053A3 (en) Methods for the generation of multispecific and multivalent antibodies
AR078254A1 (en) IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME
EA202091871A1 (en) POLISHING ANTIBODY
DE60226486D1 (en) SELF-ARRANGING MOLECULES
MX2014014065A (en) Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof.
TR201910213T4 (en) Multivalent antibodies stabilized with disulfide.
MX2016003593A (en) Multispecific domain exchanged common variable light chain antibodies.
ATE408146T1 (en) NON-COMPETITIVE IMMUNOASSAY FOR SMALL ANALYTES
EA200970954A1 (en) PENTASPECIFIC ANTIBODIES, METHODS OF THEIR RECEPTION AND APPLICATION
CY1118053T1 (en) MEDICINAL COMPOSITIONS WITH RESOLUTION IN CEA SOLUTION
PH12014501783A1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
PE20251579A1 (en) CD70-SPECIFIC ANTIBODIES AND THEIR USES
CO6231038A2 (en) UNION PROTEINS, INCLUDING ANTIBODIES DERIVED FROM ANTIBODY AND ANTIBODY FRAGMENTS THAT SPECIFICALLY JOIN CD154 AND ITS USES
NZ712765A (en) Antibodies that bind csf1r
JP2013235610A5 (en)
PE20221045A1 (en) BIESPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD3
UY31433A1 (en) NEW SPECIFIC ANTIBODIES OF PEPTIDES - AMILOIDS AND THEIR USES AS AGENTS OF DIAGNOSIS OR DRUGS
EA201691075A1 (en) METHODS OF OXYM CONJUGATION WITH KETON-MODIFIED POLYPEPTIDES
WO2021146590A3 (en) Pro-antibody that reduces off-target toxicity
SA523450918B1 (en) Anti-nectin-4 antibodies and their uses